Anti-SNCB / Beta Synuclein

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. SNCB antibody detects Beta-synuclein, a presynaptic neuronal protein belonging to the synuclein family, which also includes alpha- and gamma-synuclein. Beta-synuclein is abundant in the brain, particularly in synaptic terminals, and functions in synaptic vesicle regulation, neurotransmitter release, and neuronal plasticity. The SNCB antibody is used in neuroscience, neurodegeneration, and synaptic biology research.Beta-synuclein is encoded by the SNCB gene located on human chromosome 5q35.2. The protein is approximately 134 amino acids in length and intrinsically disordered, allowing it to adopt multiple conformations upon membrane binding. Unlike alpha-synuclein, Beta-synuclein lacks the hydrophobic non-amyloid component domain that promotes aggregation, and therefore is considered non-amyloidogenic under physiological conditions. This makes it an important natural modulator of synuclein aggregation balance.The SNCB antibody detects a 14-20 kilodalton protein by western blot and shows intense staining in synaptic regions under immunohistochemistry. Beta-synuclein associates with synaptic vesicles through lipid interactions and regulates neurotransmitter release by modulating SNARE complex dynamics. It may act as a molecular chaperone preventing pathological alpha-synuclein aggregation. Reduced expression or mutations in SNCB have been linked to dementia with Lewy bodies and Parkinson-like neurodegenerative disorders.Beta-synuclein also influences calcium signaling, vesicle recycling, and synaptic stability. Its expression is developmentally regulated, increasing as neurons mature. Under oxidative stress or protein misfolding conditions, Beta-synuclein may acquire toxic gain-of-function properties, forming soluble oligomers that disrupt vesicular trafficking. Recent evidence indicates that it may modulate dopaminergic neuron vulnerability through redox regulation and mitochondrial interactions.Beyond neurodegeneration, Beta-synuclein is expressed in certain endocrine and peripheral tissues, where it regulates vesicle release. It has potential as a biomarker for neurological diseases and as a therapeutic target to stabilize alpha-synuclein homeostasis. NSJ Bioreagents provides a validated SNCB antibody optimized for its applications, facilitating research on synaptic physiology, neurodegenerative mechanisms, and synuclein biology.